schizophrenia treatment

Teva's once-monthly schizophrenia injection TEV-749 advances toward FDA approval, aiming to improve patient medication compliance and reduce healthcare burden compared to daily oral treatments.

FDA accepts Teva's application for monthly olanzapine injection treating schizophrenia. The formulation eliminates post-injection monitoring requirements while maintaining efficacy.